Method of use for murine leukaemia inhibitory factor-binding protein (mLBP)
AssigneeAmrad Corporation Limited
InventorsNicos Anthony Nicola, Meredith Layton, Donald Metcalf, Richard J Simpson
Life of this patent
Estimating the term…
Abstract
The present invention relates to a isolated leukaemia inhibitory factor (LIF)-binding protein (LBP) in soluble form and obtainable from a first mammalian species, said LBP capable of inhibiting the ability of LIF from a second mammalian species to induce differentiation of M1 myeloid leukaemic cells in vitro to a greater extent when compared to its ability to inhibit LIF from said first mammalian species.
Claims2
A method of inhibiting the activity of humnan LIF to induce differentiation of human M1 myeloid Leukaemic cells comprising administering to a human an effective amount of mouse Leukaemia Inhibitory Factor (LCF)-binding protein (LBP) in soluble form, said LBP exhibiting at least 20-fold higher binding affinity for human LIF compared to the binding affinity for mouse LIF.
A method of inhibiting the activity of human LIF comprising administering to a human an effective amount of a soluble mouse Leukaemia Inhibitory Factor-binding protein (LBP), wherein said mouse LBP exhibits at least 20-fold higher binding affinity for human LIF compared to the binding affinity for mouse LIF.
Dependencies are inferred from the claim text.